1. Introduction {#sec1}
===============

Depression is the most common mental disorder in menopausal women, with a prevalence ranging from 26% to 41.8% \[[@B1]--[@B5]\]. Menopause represents a significant transition in the life of a woman, and it has been considered as a specific window of vulnerability to depression \[[@B6], [@B7]\]. Women with menopausal depression are related to decreased quality of life, increased cardiovascular disease, and metabolic syndrome \[[@B8]--[@B11]\].

Antidepressants are considered the most common pharmacotherapy specifically for menopausal depression. However, the effect of antidepressants is unsatisfactory clinically, and the long-term use leads to considerable adverse effects. For example, selective serotonin reuptake inhibitors (SSRIs) are associated with sexual dysfunction, weight gain, and sleep disturbance \[[@B12]--[@B14]\]. Hormone therapy (HT) is widely used to alleviate menopause-related symptoms, and it has also been used in the treatment of menopausal depression \[[@B15], [@B16]\]. However, its effectiveness was inclusive \[[@B17]\]. Therefore, alternative therapies with more benefits and fewer harms were in continuous demand.

Traditional Chinese medicine (TCM) is one of the oldest medicine systems in the world and has been widely used as a form of complementary and alternative medicine \[[@B18], [@B19]\]. In China, oral Chinese herbal medicine (OCHM) is commonly used in combination with pharmacotherapy for menopausal depression and the associated clinical studies have been conducted \[[@B20], [@B21]\]. However, most of the clinical studies were of insufficient sample size and of varied quality of methodological design. Systematic reviews on OCHM for depression \[[@B22], [@B23]\] and menopausal-related symptoms have already been published \[[@B24]\]. However, previous systematic reviews did not specifically evaluate the effectiveness of OCHM as an adjunctive therapy to pharmacotherapy for menopausal depression.

This systematic review was motivated by the large number of published clinical trials on OCHM combined with pharmacotherapy and the unresolved problems of pharmacotherapy. Our objective was to evaluate the effectiveness of OCHM combined with pharmacotherapy for menopausal depression.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

We conducted and reported the systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines \[[@B25]\]. The electronic databases were searched from their inception to December 25, 2016, comprising PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Chinese National Knowledge Infrastructure (CNKI), Wan Fang Database, Chinese Scientific Journal Database (VIP), and Chinese Biomedical (CBM) database. The combination of search terms was presence of menopause, depression, traditional Chinese medicine, and randomized controlled trial (RCT). There was no limit to the language or publication status. The search strategy is attached in the Appendix.

2.2. Eligibility Criteria {#sec2.2}
-------------------------

*Types of Studies.*Only randomized controlled trials were eligible.*Types of Participants.*Menopausal women aged 40 to 60 years with depressive symptoms were eligible. Depression was diagnosed according to the Classification and Diagnosis of Mental Diseases (CCMD-3) (Psychiatry Branch of Chinese Medical Association) \[[@B26]\], the Diagnostic and Statistical Manual (DSM-IV) (American Psychiatric Association) \[[@B27a], [@B27b]\], and the International Classification of Disease (ICD-10, WHO) (World Health Organization) \[[@B28]\].*Types of Intervention and Control.*Studies that compared OCHM plus pharmacotherapy to the same pharmacotherapy were included. All forms of OCHM (i.e., decoctions, tables, capsules, pills, and powders) were included. The pharmacotherapy included conventional antidepressants (paroxetine hydrochloride, fluoxetine hydrochloride, deanxit, and venlafaxine), HT (estradiol valerate tablets and tibolone), and a combination of antidepressants and HT. The treatment duration had to last for three weeks at least.*Types of Outcome Measurements.*The primary outcome was the total scores of Hamilton Rating Scale for Depression (HAMD). Clinically, HAMD scores have been commonly used to assess the severity of depression \[[@B29]\]. The secondary outcome was the response rate by reducing the scores of HAMD, Kupperman Menopausal Index (KMI), and adverse events (AEs).

2.3. Data Extraction and Quality Assessment {#sec2.3}
-------------------------------------------

Titles and abstracts of all retrieved studies were screened, and then full texts were reviewed for eligibility by two authors (Jiju Wang and Jian Liu) independently. The data was collected by using the predefined data extraction form, including the journal title, first author, year of publication, size of study, baseline characteristics of women (e.g., age, course of disease), methodological design, intervention strategy, treatment duration, and outcomes. The dataset was validated by the third reviewer (Xiaouyn Wang).

Two reviewers independently evaluated the risk of bias by using the Cochrane Collaboration\'s tool \[[@B30]\]. Each domain of the bias was classified as a "low risk", "unclear", or "high risk".

2.4. Data Synthesis {#sec2.4}
-------------------

Meta-analysis was performed using Review Manager (the Cochrane Collaboration) software, Version 5.3.0. For dichotomous data, relative risk ratio (RR) with 95 % confidence intervals (CIs) was used to present the therapeutic effect; for continuous data, mean difference (MD) with 95 % CIs was used. The chi-square test and the Higgins I^2^ test were used to assess heterogeneity. If heterogeneity was low (I2 \< 50% or P \> 0.1), the fixed effects model was used. If heterogeneity was high (*I*^2^ \> 50% or *P* \< 0.1), the random effect model was used and further analyses such as subgroup or sensitivity analysis were planned to clarify the source of heterogeneity.

Publication bias was visualized by the funnel chart. Begg\'s correlation test and Egger\'s intercept test were used to quantify the publication bias, with a significant level at 0.05.

3. Results {#sec3}
==========

3.1. Study Selection {#sec3.1}
--------------------

Databases search found 1076 articles. After duplicates were removed, 761 articles were screened by reading the title/abstract and 628 ineligible articles were removed. After reading the full texts of the remaining 133 articles, 22 trials \[[@B31]--[@B52]\] were finally included in the systematic review. The flowchart summarizes the screening process ([Figure 1](#fig1){ref-type="fig"}).

3.2. Study Characteristics {#sec3.2}
--------------------------

All included trials were conducted in China and they were published ranging from 2005 to 2016. The total sample size was 1777, including 901 women in the experimental group and 876 women in the control group. The participants ranged between 40 and 60 years. The most common diagnostic instrument was CCMD-3, and the combination of CCMD-3 and HAMD score was usually used as the inclusion criterion of RCTs. For outcome measurements, eighteen trials reported HAMD score \[[@B31]--[@B33], [@B35]--[@B39], [@B41]--[@B45], [@B48]--[@B52]\], eighteen calculated response rate by reducing HAMD scores \[[@B32], [@B34]--[@B38], [@B40]--[@B48], [@B50]--[@B52]\], and three trials reported KMI score \[[@B38], [@B41], [@B44]\]. AEs were reported in 10 trails \[[@B31], [@B36]--[@B38], [@B40], [@B42], [@B44], [@B45], [@B50]\]. The basic characteristics of the included studies are summarized in [Table 1](#tab1){ref-type="table"}.

Four forms of OCHM were investigated, consisting of decoctions, capsule, granule, and powder. Twenty-two formulas of OCHM were found. Bupleuri Radix (Chinese name: Chaihu) and Paeoniae Radix Alba (Chinese name: Baishao) were the herbs with top frequency. Details of OCHM in the included studies are summarized in [Table 2](#tab2){ref-type="table"}. Control group included three categories of pharmacologic agents, antidepressants in 13 trials \[[@B31], [@B36]--[@B40], [@B43]--[@B48], [@B51]\], HT in 2 trials \[[@B41], [@B52]\], and the combination of antidepressants and HT in 6 trials \[[@B32]--[@B35], [@B49], [@B50]\]. One trial did not specify the pharmacotherapy \[[@B42]\]. The treatment duration ranged from three to 12 weeks.

3.3. Risk of Bias {#sec3.3}
-----------------

The risk of bias was summarized in Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}. For random sequence generation, six trials used random number tables \[[@B31], [@B38], [@B41], [@B44], [@B45], [@B51]\], and 13 trials \[[@B32]--[@B34], [@B36], [@B37], [@B39], [@B40], [@B42], [@B46]--[@B49], [@B52]\] did not provide details of randomization. Three trials considered the order of visits as random, which were of high risks in selection bias \[[@B35], [@B43], [@B50]\]. None of the trials reported allocation concealment. Binding of participants, personnel, and outcome assessors was not applied in any studies. None of the studies had attribution bias. The risk of bias in selective reporting was unclear as none of the studies published their protocols.

3.4. Effect of Intervention {#sec3.4}
---------------------------

### 3.4.1. Hamilton Rating Scale for Depression (HAMD) Scores {#sec3.4.1}

Eighteen RCTs (n = 1417 participants) used HAMD scores to measure the effect of OCHM for menopausal depression \[[@B31]--[@B33], [@B35]--[@B39], [@B41]--[@B45], [@B48]--[@B52]\]. Overall, the adjuvant use of OCHM therapy in pharmacotherapy was superior to pharmacotherapy alone (mean difference (MD) = −3.75; 95% CI = −5.22, −2.29; I^2^ = 94%; random model) ([Figure 4](#fig4){ref-type="fig"}).

As the meta-analysis was heterogeneous, subgroup analysis in terms of different categories of pharmacologic agents was performed ([Figure 4](#fig4){ref-type="fig"}). The subgroup analysis showed that adjuvant therapy of OCHM for menopausal depression was more effective than antidepressants alone (MD = −2.58; 95% CI = −4.33, −0.83; I^2^ = 95%) \[[@B31], [@B36]--[@B39], [@B43]--[@B45], [@B48], [@B51]\]. It was superior to HT alone (MD = −7.94; 95% CI = −14.90, −0.97; I^2^ = 81%) \[[@B41], [@B52]\] and antidepressants combined with HT (MD = −4.11; 95% CI = −5.97, −2.24; I^2^ = 69%; random model) \[[@B32], [@B33], [@B35], [@B49], [@B50]\]. Another study \[[@B42]\] did not specify the pharmacotherapy.

### 3.4.2. Response Rate {#sec3.4.2}

Eighteen trials (n = 1189 participant) applied response rate of reducing HAMD scores in outcome measurement \[[@B32], [@B34]--[@B38], [@B40]--[@B48], [@B50]--[@B52]\]. The overall meta-analysis showed OCHM adjuvant therapy for menopausal depression was superior to pharmacotherapy (RR = 1.17; 95% CI = 1.10, 1.25; I^2^ = 55%; random model) ([Figure 5](#fig5){ref-type="fig"}).

### 3.4.3. Kupperman Menopausal Index (KMI) Scores {#sec3.4.3}

Three RCTs \[[@B38], [@B41], [@B44]\] measured the effectiveness of OCHM for menopausal depression by using KMI scores. Meta-analysis showed OCHM combined with pharmacotherapy was more effective than pharmacotherapy alone (MD = −4.68; 95% CI = −7.26, −2.11; I^2^ = 69%; random model) ([Figure 6](#fig6){ref-type="fig"}).

### 3.4.4. Adverse Events (AEs) {#sec3.4.4}

AEs were monitored in nine studies (n = 797 participants) \[[@B31], [@B36]--[@B38], [@B40], [@B42], [@B44], [@B45], [@B50]\]. Meta-analysis showed that the incident of adverse events in the group of OCHM plus pharmacotherapy was less than the pharmacotherapy (RR = 0.25; 95% CI = 0.16, 0.38; I^2^ = 14%; fixed model) ([Figure 7](#fig7){ref-type="fig"}).

3.5. Publication Bias {#sec3.5}
---------------------

The funnel plots of HAMD scores and the response rate were asymmetrical (Figures [8](#fig8){ref-type="fig"} and [9](#fig9){ref-type="fig"}). The regression analysis of Begg\'s rank correlation test and Egger\'s intercept test was statistically significant (*P* \> 0.05), suggesting the presence of publication bias. The detection of publication bias was not available for other outcomes as the included studies were less than 10.

4. Discussion {#sec4}
=============

4.1. Statement of Principal Findings {#sec4.1}
------------------------------------

In the present study, we reviewed 22 RCTs involving a total of 1777 participants and assessed the add-on effects and safety of OCHM to pharmacotherapy in women with menopausal depression. Meta-analysis showed that the combination of OCHM and pharmacotherapy was more effective in improving menopausal depression. In addition, the incidence of AEs in the participants treated with OCHM adjunctive therapy was less than those without OCHM adjunctive therapy. However, the risk of bias of the included RCTs may affect the evidence certainty; particularly most studies did not blind the participants or personnel.

4.2. Possible Explanations for the Evidence {#sec4.2}
-------------------------------------------

OCHM can increase the expression level of estrogen receptors in hypothalamic pituitary ovarian (HPO) axis \[[@B53], [@B54]\]. OCHM can also alleviate hippocampal neuron damage, inhibit early apoptosis of neurons, and increase the content of monoamine transmitters in brain tissue through the CREB-BDNF signaling pathway \[[@B55]\]. Furthermore, OCHM can regulate the hypothalamus pituitary adrenal (HPA) axis in menopausal depression rats and improve the behavior of model rats \[[@B56]\]. Bupleuri Radix (Chinese name: Chaihu) and Paeoniae Radix Alba (Chinese name: Baishao) were the herbs with top frequency. Bupleurum-saikoside, the main active ingredient of Bupleuri Radix, improved depression by regulating the monoamine neurotransmitters and BDNF in the brain \[[@B57]\]. Paeoniae Radix Alba improved depression by increasing the single amine neurotransmitter and adjusting the dysfunction of HPA axis \[[@B58]\].

4.3. Limitations and Implications of the Research {#sec4.3}
-------------------------------------------------

There were several limitations in this study. Firstly, the quality of the included trials was generally poor. The risks of selection bias and reporting bias were unclear most of the time. And the risk of performance bias in almost all the RCTs was high. These biases may affect the results of meta-analysis. Secondly, the heterogeneity was observed across meta-analyses and it was not resolved by subgroup analysis. This can also reduce the evidence certainty. Thirdly, none of the RCTs included considered placebo as the control. Hence the current studies were unable to conclude the efficacy of OCHM. Although it is difficult to successfully produce a placebo to CHM because of its special characteristics such as the appearance, smell, and taste, recent progress of placebo making can be applied. For example, when researchers explored the preparation method of placebo to Moron Dan, they found that the flavor characteristics and disintegration of the placebo made of soybean powder 100g, starch 100g, carbon black pigment 1g, and honey 70g were similar to the experimental drug \[[@B59]\]. Some researchers suggested that encrypted capsules could be also used as a placebo \[[@B60]\].

5. Conclusion {#sec5}
=============

Adjuvant therapy of OCHM provided additional benefits to pharmacotherapy in the people with menopausal depression. More RCTs with a rigorous design, particularly applying placebo as the control as well as blinding the participants and personnel, are needed to confirm the efficacy of OCHM for menopausal depression.
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 {#secA}

Search strategy included the following:\#1 Menopause \[Mesh\]\#2 ((((((((((Perimenopausal \[ti.ab\]) OR menopausal \[ti.ab\]) OR menopause \[ti.ab\]) OR perimenopause \[ti.ab\]) OR premenopause \[ti.ab\]) OR postmenopause \[ti.ab\]) OR menopausal transition\[ti.ab\]) OR premenopausal \[ti.ab\]) OR postmenopausal \[ti.ab\]) OR climacterium \[ti.ab\]) OR climacteric \[ti.ab\]\#3 \#1 OR \#2\#4 Depression \[Mesh\]\#5 (((((((((Depression \[ti.ab\]) OR Depressions \[ti.ab\]) OR Depressive Symptoms \[ti.ab\]) OR Depressive Symptom \[ti.ab\]) OR Symptom, Depressive \[ti.ab\]) OR Symptoms, Depressive \[ti.ab\]) OR Emotional Depression \[ti.ab\]) OR Depression, Emotional \[ti.ab\]) OR Depressions, Emotional \[ti.ab\]) OR Emotional Depressions \[ti.ab\]\#6 \#4 OR \#5\#7 Medicine, Chinese Traditional \[Mesh\]\#8 ((((((Medicine, Chinese Traditional \[ti.ab\]) OR Traditional Chinese Medicine \[ti.ab\]) OR Chinese Medicine, Traditional \[ti.ab\]) OR Chung I Hsueh \[ti.ab\]) OR Hsueh, Chung I \[ti.ab\]) OR Zhong Yi Xue \[ti.ab\]) OR Chinese Traditional Medicine \[ti.ab\]) OR Traditional Medicine, Chinese \[ti.ab\]\#9 \#7 OR \#8\#10 ((randomized controlled trial \[Publication Type\]) OR randomized \[ti.ab\]) OR placebo \[ti.ab\]\#11 \#3 AND \#6 AND \#9 AND \#10
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###### 

Basic characteristics of the included studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference        Sample size(I/C)   Age(I/C)                                    Duration of disease(I/C)           Diagnosis standard   Intervention group           Control group         Treatment duration   *Outcome*
  ---------------- ------------------ ------------------------------------------- ---------------------------------- -------------------- ---------------------------- --------------------- -------------------- -----------
  Chen H, 2012     68/51              42-59 (50.20 ± 3.94)\                       1.76 ± 0.99 y\                     Age;\                OCHM + antidepressant        antidepressant        8w                   ①②④
                                      /43-58 (50.78 ± 4.08)                       /1.91 ± 1.25 y                     CCMD-3;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Chu YH, 2005     30/30              41-60 (47.86 ± 4.42) /41-60 (48.3 ± 4.06)   NS                                 Age;\                OCHM + HT                    HT                    6w                   ①②
                                                                                                                     CCMD-3;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Guo LH, 2016     43/43              40-55/42-55                                 (1.8 ± 0.6) y/(1.6 ± 0.8) y        Age;\                OCHM + antidepressant        antidepressant        6w                   ②
                                                                                                                     CCMD-3;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Jiang LX, 2016   98/98              41-60 (51.18 ± 4.52)/46-54(48.85 ± 3.27)    (4.8 ± 1.7) y/(4.2 ± 1.0) y        Age;\                OCHM + antidepressant        antidepressant        8w                   ①②③④
                                                                                                                     CCMD-3;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Li QY, 2009      34/34              41-56 (46.8 ± 4.1)                          NS                                 Age;\                OCHM + pharmacotherapy       pharmacotherapy       4w                   ①②④
                                                                                                                     ICD-10;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Liu F, 2014      50/50              44-56 (49.3 ± 2.4)\                         (2.3 ± 0.5) y/(2.1 ± 0.4)y         Age;\                OCHM + antidepressant        antidepressant        8w                   ①②
                                      /43-57 (48.4 ± 2.3)                                                            ICD-10                                                                                       

                                                                                                                                                                                                                  

  Liu R, 2007      30/30              (54.32 ± 3.29)\                             (11.32 ± 6.25) m/(12.12 ± 4.58)m   Age;\                OCHM + antidepressant        antidepressant        8w                   ①②④
                                      /(54.0 ± 4.62)                                                                 CCMD-3;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Ni JP, 2014      37/33              (52 ± 4)/(52 ± 4)                           (9 ± 5) m/\                        Age;\                OCHM + antidepressant        antidepressant        4w                   ②④
                                                                                  (9 ± 5) m                          CCMD-3;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Qu LX, 2010      30/30              45-55(51.6 ± 3.2)\                          (10.5±2.7)m\                       Age;\                OCHM + HT + antidepressant   HT + antidepressant   8w                   ①②④
                                      /45-55(50.8 ± 2.8)                          /(11.1±5.2)m                       CCMD-3;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Shi LR, 2016     45/45              41-58(46.4 ± 4.2)\                          (11.7 ± 4.5)m\                     Age;\                OCHM + HT + antidepressant   HT + antidepressant   12w                  ①②
                                      /42-57(44.8 ± 3.3)                          /(10.6 ± 6.3)m                     CCMD-3;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Sun GC, 2015     40/40              42.2 ± 2.60\                                (1.92 ± 1.06) y /NS                Age;\                OCHM + antidepressant        antidepressant        4w                   ①
                                      /42.2 ± 2.60                                                                   ICD-10;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Sun YH, 2013     38/38              43-48(44.76 ± 2.24)\                        (2.38 ± 1.24) y\                   Age;\                OCHM + HT + antidepressant   HT + antidepressant   4w                   ②
                                      /42-49(45.02 ± 3.15)                        /(2.54 ± 1.56)y                    CCMD-3;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Wang CG, 2015    46/46              44-53(46.93 ± 6.8)\                         NS                                 Age;\                OCHM + antidepressant        antidepressant        6w                   ①④
                                      /44-53(47.52 ± 7.2)                                                            CCMD-3                                                                                       

                                                                                                                                                                                                                  

  Wang SF, 2015    40/40              43-50(46.45 ± 6.15)\                        (2.75 ± 0.35)y\                    Age;\                OCHM + HT + antidepressant   HT + antidepressant   3w                   ①
                                      /42-49(45.82 ± 5.45)                        /(2.85 ± 0.43)y                    CCMD-3;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Wang XL, 2011    60/60              45-55(51.21 ± 3.17)\                        NS                                 Age;\                OCHM + HT + antidepressant   HT + antidepressant   8w                   ①
                                      /45-55(50.86 ± 3.41)                                                           CCMD-3;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Wang Y, 2015     30/30              45.20 ± 2.90\                               NS                                 Age;\                OCHM + antidepressant        antidepressant        8w                   ①②③④
                                      /44.80 ± 3.10                                                                  ICD-10;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Zhang CH, 2013   40/40              43-56(46.80 ± 4.10)\                        (11.50±4.30)m\                     Age;\                OCHM + HT + antidepressant   HT + antidepressant   3w                   ①②
                                      /44-55(45.40 ± 3.2)                         /(10.90±6.50)m                     CCMD-3;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Zhang CH, 2011   30/30              45-55(43.50 ± 12.43)\                       NS                                 Age;\                OCHM + antidepressant        antidepressant        6w                   ①②
                                      /45-55(42.25 ±11.38)                                                           CCMD-3;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Zhang GQ, 2009   38/34              45-56(51.63 ± 3.68)\                        (9.44 ± 4.69)m\                    Age;\                OCHM + antidepressant        antidepressant        4w                   ①②④
                                      /45-56(51.95 ± 3.86)                        /(8.88 ± 4.65) m                   CCMD-3;\                                                                                     
                                                                                                                     HAMD                                                                                         

                                                                                                                                                                                                                  

  Zhang HZ, 2014   20/20              45-53\                                      (6-24)m\                           Age;\                OCHM + HT                    HT                    12w                  ①②③
                                      /46-52                                      /(5-22)m                           CCMD-3                                                                                       

                                                                                                                                                                                                                  

  Zhang SJ, 2012   27/27              43-54(46.5 ± 6.3)\                          (3.2 ± 2.8)m\                      Age;\                OCHM + antidepressant        antidepressant        4w                   ②
                                      /44-55(45.3 ± 7.2)                          /(4.1 ± 3.2)m                      DSM-IV                                                                                       

                                                                                                                                                                                                                  

  Zhang XH, 2014   27/27              (47 ± 6.8)\                                 NS                                 Age;\                OCHM + antidepressant        antidepressant        8w                   ①②
                                      /(46.0 ± 6.8)                                                                  CCMD-3;\                                                                                     
                                                                                                                     HAMD                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CCMD-3: Criteria for Classification and Diagnosis of Mental Diseases; DSM-IV: Diagnostic and Statistical Manual; ICD-10: International Classification of Disease; m = month; y = year; NS: not stated.OCHM: oral Chinese herbal medicine; HT: hormone therapy; w = week; ①: Hamilton Rating Scale for Depression (HAMD) score; ②: response rate; ③: Kupperman Menopausal Index (KMI) score; ④: adverse events (AEs).

###### 

Chinese herbal medicine of the included studies.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study            Formula                                    ^a^ Herbal ingredients                                                                                                                                               Preparation   Dosage                  Frequency
  ---------------- ------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ----------------------- -----------
  Chen H, 2012     Jie Yu Jing Xin Ke Li                      zhenzhumu, huaixiaomai, shoudihuang, shanzhuyu, tusizi, suanzaoren, fuling, chaihu, baishao, meiguihua, danggui, nvzhenzi                                            granule       1 bag                   bid

                                                                                                                                                                                                                                                                         

  Chu YH, 2005     Xiao Yao Jie Yu Tang                       Chaihu, danggui, baishao, baizhu, fuling, weijiang, bohe, zhi gan cao, xian ling pi, nvzhenzi, shengmaiya, chaomaiya                                                 decoction     1 pack decocted twice   bid

                                                                                                                                                                                                                                                                         

  Guo LH, 2016     Bai He Di Huang Tang                       Baihe, sheng di huang, long gu, muli, danggui, he huan pi, chaihu, ye jiao teng, fushen, yujin, zhi mu                                                               decoction     1 pack decocted twice   bid

                                                                                                                                                                                                                                                                         

  Jiang LX, 2016   Wu Ling Jiao Nang                          wulingjun                                                                                                                                                            capsule       3 tablets               tid

                                                                                                                                                                                                                                                                         

  Li QY, 2009      Jie Yu Tang                                Dangshen, chuanxiong, danggui, danshen, xiangfu, he huan pi, gualou, yujin                                                                                           decoction     1 pack decocted twice   bid

                                                                                                                                                                                                                                                                         

  Liu F, 2014      Suan Zao Ren Tang                          Suanzaoren, chuanxiong, fuling, wuweizi, zhi mu, gan cao                                                                                                             decoction     1 pack decocted twice   bid

                                                                                                                                                                                                                                                                         

  Liu R, 2007      Xue Fu Zhu Yu Jiao Nang                    Taoren, honghua, chishao, chuanxiong, zhiqiao, chaihu, jiegeng, danggui, dihuang, niuxi, gan cao                                                                     capsule       6 tablets               bid

                                                                                                                                                                                                                                                                         

  Ni JP, 2014      Shen Song Yang Xin Jiao Nang               Renshen, maidong, shanzhuyu, danshen, suanzaoren, sangjishen, chishao, tu bie chong, gansong, huanglian, wuweizi, long gu                                            capsule       4 tablets               tid

                                                                                                                                                                                                                                                                         

  Qu LX, 2010      Jie Yu Zi Shen Tang                        Chaihu, xiangfu, baishao, baizhu, yujin, gan cao, suanzaoren, fuling, shichangpu, shoudihuang, shanyurou, shanyao                                                    decoction     1 pack decocted twice   bid

                                                                                                                                                                                                                                                                         

  Shi LR, 2016     Zi Ni Zi Gan Yang Shen Tang                Fuling, gan cao, baishao, chaihu, chuanxiong                                                                                                                         decoction     1 pack decocted twice   bid

                                                                                                                                                                                                                                                                         

  Sun GC, 2015     Jia Wei Xiao Yao San                       Chaihu, baizhu, bohe, danggui, fuling, baishao, gan cao, shengjiang, zhizi, danpi                                                                                    granule       1 bag                   tid

                                                                                                                                                                                                                                                                         

  Sun YH, 2013     Zi Ni Shu Gan Jie Yu Tang                  Chaihu, xiangfu, chuanxiong, chishao, yujin, chenpi, sheng di huang, shanzhuyu, danpi, yuanzhi, gan cao                                                              decoction     1 pack decocted twice   bid

                                                                                                                                                                                                                                                                         

  Wang CG, 2015    Zi Ni An Shen Jie Yu Tang                  Huangqi, huangqin, chaihu, muxiang, zhiqiao, gan cao, sharen, peilan, dangshen, fushen, danggui, baizhu, chuanxiong, yujin, suanzaoren, ye jiao teng, long yan rou   decoction     1 pack decocted twice   bid

                                                                                                                                                                                                                                                                         

  Wang SF, 2015    Zi Ni Shu Gan Jie Yu Tang                  Chaihu, xiangfu, chuanxiong, baishao, yujin, chenpi, zhi mu, shengdi, shanzhuyu, danpi, suanzaoren, gan cao                                                          decoction     1 pack decocted twice   bid

                                                                                                                                                                                                                                                                         

  Wang XL, 2011    Si Hua Jie Yu Tang                         He huan hua, xuanhua, meiguihua, baimeihua, suanzaoren, bai zi ren, fuxiaomai, fushen, ye jiao teng, tiandong, maidong, wuweizi, gan cao, dazao                      decoction     1 pack decocted twice   bid

                                                                                                                                                                                                                                                                         

  Wang Y, 2015     Zi Ni Bai He Di Huang Tang                 Baihe, shengdi, maidong, wuweizi, he huan pi, ye jiao teng, fuling, yuanzhi, shichangpu, yujin, chuanxiong, gan cao                                                  decoction     1 pack decocted twice   bid

                                                                                                                                                                                                                                                                         

  Zhang CH, 2013   Wu Ling Jiao Nang                          wulingjun                                                                                                                                                            capsule       3 tablets               tid

                                                                                                                                                                                                                                                                         

  Zhang CH, 2011   Zi Ni Zi Yin Bu Shen Tang                  Chaihu, xiangfu, chuanxiong, baishao, yujin, shoudihuang, fuling, shanzhuyu, suanzaoren, gan cao                                                                     decoction     1 pack decocted twice   bid

                                                                                                                                                                                                                                                                         

  Zhang GQ, 2009   Zi Ni Zao Ren Bu Xue\                      Suanzaoren, fuling, chuanxiong, zhi mu, gan cao, huangqi, danggui, shanzhuyu, shoudihuang, danshen, chaihu, xiangfu, yujin, shichangpu                               decoction     1 pack decocted twice   bid
                   Tang\                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                         

  Zhang HZ, 2014   Si Er Wu He Fang And Gan Mai Da Zao Tang   Danggui, baishao, danshen, shoudihuang, xianmao, xian ling pi, fu pen zi, tusizi, wuweizi, che qian zi, gouqi, yujin, huanglian, rougui, xiaomai, gan cao, dazao     decoction     1 pack decocted twice   bid

                                                                                                                                                                                                                                                                         

  Zhang SJ, 2012   Zi Ni Bai He Di Huang Tang                 Baihe, shengdi, danshen, chuanxiong, juhua                                                                                                                           decoction     1 pack decocted twice   bid

                                                                                                                                                                                                                                                                         

  Zhang XH, 2014   Kun Tai Jiao Nang                          Shoudihuang, huanglian, baishao, huangqin, ejiao, fuling                                                                                                             capsule       4 tablets               tid
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ The herbal ingredients are presented as Chinese pinyin. Bid: twice per day; tid: three times per day.

[^1]: Academic Editor: Shan-Yu Su
